A Phase 2 interventional study of Placebo and Levonorgestrel in Endometriosis, sponsored by Bayer. Completed at 117 sites in 14 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-07.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Endometriosis by Bayer — none open to participants now, none under way, none of them phase 3. Endometriosis · Bayer.
Among the 27 studies in Endometriosis by Bayer, this one has the largest enrollment of the 20 interventional ones that give a count, is the only one that started in 2014, is one of 6 in phase 2, and was the 10th registered.
921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.
Browse Endometriosis studies →None of the 27 studies in Endometriosis by Bayer is open now. The open studies under Endometriosis, anywhere →
Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 319 is above the median of 67 across 541 interventional studies indexed under Endometriosis.
Median enrollment 68 across the 20 interventional studies, 895 across the 7 observational. Of the 27 that completed or were terminated, 3 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Endometriosis by Bayer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Purpose of the study is to test efficacy and safety of BAY98-7196 intravaginal ring as a new treatment option for patients with endometriosis-associated pelvic pain
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
Drug: Placebo
Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
Drug: Placebo · Drug: Levonorgestrel
Anastrozole 300 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
Drug: Placebo · Drug: Anastrozole
Anastrozole 600 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
Drug: Placebo · Drug: Anastrozole
Anastrozole 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
Drug: Placebo · Drug: Anastrozole
Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
Drug: Placebo · Drug: Lupron / Leuprolide acetate
Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
Participants received Anastrozole 300 µg/d or 600 µg/d or 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
Drug page: Leuprolide
Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to End of Treatment (Last 28 Days of Treatment Period, Days 57-84) as Measured on NRS by Question 1 of ESD
Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, participants were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The mean pain of the 7 days with worst EAPP within a 28-day window was calculated as the sum of ESD item 1 on 7 days with worst EAPP within that 28-day window divided by 7.
Time frame: Baseline (last 28 days before randomization), end of treatment (Treatment 3) (last 28 days of the treatment period, Day 57-84)
Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to First Cycle Under Study Treatment (Day 1-28) and to Second Cycle Under Study Treatment (Day 29-56) as Measured on NRS by Question 1 of ESD
Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The mean pain of the 7 days with worst EAPP within a 28-day window was calculated as the sum of ESD item 1 on 7 days with worst EAPP within that 28-day window divided by 7.
Time frame: Baseline (last 28 days before randomization), first cycle (Treatment 1) (Day 1-28), second cycle (Treatment 2) (Day 29-56)
Absolute Change in Mean Pain From Baseline (Last 28 Days Before Randomization) to First Cycle Under Study Treatment(Day1-28), Second Cycle Under Study Treatment(Day29-56),Third Cycle Under Study Treatment (Day57-84) as Measured on NRS by Question1 of ESD
Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The mean pain within a 28-day window was calculated as the sum of ESD item 1 within that 28-day window divided by the number with non-missing days within that 28-day window. Here, number of subjects 'n' signifies evaluable subjects for the respective category.
Time frame: Baseline (last 28 days before randomization), first cycle (Treatment 1) (Day 1-28), second cycle (Treatment 2) (Day 29-56), and third cycle (Treatment 3) (last 28 days of the treatment period, Day 57-84)
Percentage of Days During Baseline (Last 28 Days Before Randomization) and Cycles 1, 2, and 3 With Pain Greater Than or Equal to (>=) 7 as Measured on NRS by Question 1 of ESD as Measured on NRS by Question 1 of ESD
Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain \>=7 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that 28-day window where item 1 of the ESD was \>=7.
Time frame: Baseline (last 28 days before randomization), Cycle 1 (Treatment 1), Cycle 2 (Treatment 2), and Cycle 3 (Treatment 3)
Change From Baseline (Last 28 Days Before Randomization) to Cycle 1, 2, and 3 in Percentage of Days With Pain >=7 as Measured on NRS by Question 1 of ESD
Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain \>=7 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that 28-day window where item 1 of the ESD was \>=7. Here, number of subjects 'n' signifies evaluable subjects for the respective category.
Time frame: Baseline (last 28 days before randomization), Cycle 1 (Treatment 1), Cycle 2 (Treatment 2), and Cycle 3 (Treatment 3)
Percentage of Days During Baseline (Last 28 Days Before Randomization) and Cycles 1, 2, and 3 With Pain >=4 as Measured on NRS by Question 1 of ESD
Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain \>=4 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that window where Item 1 of the ESD was \>=4. Here, number of subjects 'n' signifies evaluable subjects for the respective category.
Time frame: Baseline (last 28 days before randomization), Cycle 1 (Treatment 1), Cycle 2 (Treatment 2), and Cycle 3 (Treatment 3)
Change From Baseline (Last 28 Days Before Randomization) to Cycle 1, 2, and 3 in Percentage of Days With Pain >=4 as Measured on NRS by Question 1 of ESD
Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain \>=4 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that window where Item 1 of the ESD was \>=4. Here, number of subjects 'n' signifies evaluable subjects for the respective category.
Time frame: Baseline (last 28 days before randomization), Cycle 1 (Treatment 1), Cycle 2 (Treatment 2), and Cycle 3 (Treatment 3)
Study was conducted in fourteen countries in Austria, Belgium, Canada, Czech Republic, Denmark, Finland, Germany, Japan, Netherlands, Norway, Poland, Spain, Switzerland, United States, between 16 October 2014 (first participant first visit) and 24 October 2016 (last participant last visit).
| Milestone | LNG 40 mcg IVR + Placebo Injection | ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection | Placebo IVR + Leuprorelin Injection | Placebo IVR + Placebo Injection |
|---|---|---|---|---|---|---|
| Started | 52 | 53 | 55 | 53 | 53 | 53 |
| Treated | 49 | 50 | 54 | 49 | 50 | 53 |
| Completed | 45 | 39 | 50 | 46 | 46 | 46 |
| Not completed | 7 | 14 | 5 | 7 | 7 | 7 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 0 | 0 | 3 |
| Withdrew: Adverse event | 4 | 8 | 3 | 4 | 3 | 3 |
| Withdrew: Other reasons | 1 | 2 | 0 | 2 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 2 | 1 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 2 | 0 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 |
Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, participants were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The mean pain of the 7 days with worst EAPP within a 28-day window was calculated as the sum of ESD item 1 on 7 days with worst EAPP within that 28-day window divided by 7.
| units on a scale | LNG 40 mcg IVR + Placebo Injection | ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection | Placebo IVR + Leuprorelin Injection | Placebo IVR + Placebo Injection |
|---|---|---|---|---|---|---|
| Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to End of Treatment (Last 28 Days of Treatment Period, Days 57-84) as Measured on NRS by Question 1 of ESD | -1.8974 ± 1.6416 | -1.6061 ± 1.6652 | -2.4014 ± 2.1833 | -2.2653 ± 1.5972 | -3.7679 ± 2.3507 | -2.293 ± 1.8247 |
Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The mean pain of the 7 days with worst EAPP within a 28-day window was calculated as the sum of ESD item 1 on 7 days with worst EAPP within that 28-day window divided by 7.
| units on a scale | LNG 40 mcg IVR + Placebo Injection | ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection | Placebo IVR + Leuprorelin Injection | Placebo IVR + Placebo Injection |
|---|---|---|---|---|---|---|
| Change at Treatment 1 | -0.7582 ± 1.1518 | -0.6849 ± 1.3832 | -1.1463 ± 1.3992 | -1.0000 ± 1.2579 | -1.2071 ± 1.1978 | -0.9048 ± 1.1686 |
| Change at Treatment 2 | -1.6447 ± 1.4831 | -1.5126 ± 2.0161 | -2.1224 ± 2.2791 | -1.9959 ± 1.3978 | -2.8607 ± 2.0665 | -1.8022 ± 1.5131 |
Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The mean pain within a 28-day window was calculated as the sum of ESD item 1 within that 28-day window divided by the number with non-missing days within that 28-day window. Here, number of subjects 'n' signifies evaluable subjects for the respective category.
| units on a scale | LNG 40 mcg IVR + Placebo Injection | ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection | Placebo IVR + Leuprorelin Injection | Placebo IVR + Placebo Injection |
|---|---|---|---|---|---|---|
| Baseline | 6.0938 ± 1.5314 | 5.7409 ± 1.3044 | 6.3694 ± 1.5300 | 5.7128 ± 1.4415 | 6.3962 ± 1.4575 | 5.6399 ± 1.5312 |
| Change at Treatment 1 | -0.8472 ± 1.1905 | -0.9009 ± 1.3434 | -1.0931 ± 1.4002 | -1.1257 ± 1.3317 | -1.5315 ± 1.4809 | -0.9777 ± 1.0680 |
| Change at Treatment 2 | -1.5774 ± 1.6278 | -1.5068 ± 1.8707 | -1.7349 ± 1.9403 | -1.9615 ± 1.3966 | -2.6855 ± 2.0601 | -1.8994 ± 1.3069 |
| Change at Treatment 3 | -1.8001 ± 1.7687 | -1.6411 ± 1.8071 | -2.0112 ± 1.9575 | -2.1268 ± 1.6877 | -3.502 ± 2.3096 | -2.2228 ± 1.4957 |
Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain \>=7 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that 28-day window where item 1 of the ESD was \>=7.
| percentage of days | LNG 40 mcg IVR + Placebo Injection | ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection | Placebo IVR + Leuprorelin Injection | Placebo IVR + Placebo Injection |
|---|---|---|---|---|---|---|
| Treatment 1 | 35.6034 ± 34.3126 | 27.5659 ± 27.6426 | 40.0813 ± 37.2694 | 23.9322 ± 28.6234 | 28.2015 ± 28.8430 | 25.1742 ± 24.2811 |
| Treatment 2 | 25.6257 ± 33.9315 | 22.8695 ± 28.3443 | 34.4364 ± 40.5623 | 14.9331 ± 23.8028 | 12.1320 ± 25.1638 | 14.1869 ± 17.7364 |
| Treatment 3 | 23.1293 ± 33.9451 | 19.9332 ± 26.0540 | 29.8103 ± 39.0434 | 14.3362 ± 25.6770 | 8.5351 ± 20.7819 | 12.7574 ± 18.5154 |
Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain \>=7 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that 28-day window where item 1 of the ESD was \>=7. Here, number of subjects 'n' signifies evaluable subjects for the respective category.
| percentage of days | LNG 40 mcg IVR + Placebo Injection | ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection | Placebo IVR + Leuprorelin Injection | Placebo IVR + Placebo Injection |
|---|---|---|---|---|---|---|
| Change at Treatment 1 | -13.6756 ± 22.6822 | -12.5862 ± 21.4336 | -15.0341 ± 21.0071 | -13.3722 ± 19.6416 | -19.8898 ± 25.9273 | -16.0105 ± 19.0190 |
| Change at Treatment 2 | -24.1404 ± 28.5082 | -17.2826 ± 29.0007 | -20.6791 ± 30.2152 | -22.3713 ± 24.4098 | -36.3540 ± 34.9706 | -26.9979 ± 24.9493 |
| Change at Treatment 3 | -26.4197 ± 31.4648 | -20.8529 ± 28.3939 | -25.3052 ± 33.5497 | -22.9682 ± 28.8677 | -39.9516 ± 33.8277 | -28.4273 ± 29.6186 |
Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain \>=4 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that window where Item 1 of the ESD was \>=4. Here, number of subjects 'n' signifies evaluable subjects for the respective category.
| percentage of days | LNG 40 mcg IVR + Placebo Injection | ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection | Placebo IVR + Leuprorelin Injection | Placebo IVR + Placebo Injection |
|---|---|---|---|---|---|---|
| Treatment 1 | 71.8037 ± 32.3658 | 69.3092 ± 27.8642 | 73.8956 ± 31.6868 | 70.6504 ± 27.8528 | 70.2066 ± 28.9333 | 65.9074 ± 30.0166 |
| Treatment 2 | 61.8199 ± 37.1217 | 57.8777 ± 34.7429 | 62.5822 ± 37.6989 | 52.6028 ± 35.6106 | 54.0965 ± 38.9629 | 49.487 ± 31.3566 |
| Treatment 3 | 60.2902 ± 37.8585 | 57.0171 ± 34.3642 | 56.7691 ± 40.3803 | 50.7332 ± 36.2903 | 38.6986 ± 39.6045 | 47.0976 ± 35.3227 |
Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain \>=4 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that window where Item 1 of the ESD was \>=4. Here, number of subjects 'n' signifies evaluable subjects for the respective category.
| percentage of days | LNG 40 mcg IVR + Placebo Injection | ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection | Placebo IVR + Leuprorelin Injection | Placebo IVR + Placebo Injection |
|---|---|---|---|---|---|---|
| Change at Treatment 1 | -12.8228 ± 20.4330 | -15.4147 ± 24.0608 | -15.1334 ± 22.5347 | -15.1947 ± 21.1740 | -21.4331 ± 23.4546 | -14.5323 ± 20.9670 |
| Change at Treatment 2 | -22.4950 ± 28.1535 | -26.8462 ± 32.6194 | -26.4468 ± 34.4661 | -33.2423 ± 27.3686 | -37.7330 ± 36.9484 | -30.9527 ± 25.4665 |
| Change at Treatment 3 | -23.5498 ± 30.2853 | -27.4770 ± 34.2051 | -32.2600 ± 37.4997 | -35.1119 ± 30.9316 | -53.4266 ± 38.8452 | -33.3421 ± 25.7105 |
Collected over From start of study treatment up to 30 days after end of treatment (Day 114). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LNG 40 mcg IVR + Placebo Injection | — | 2/49 (4.1%) | 38/49 (77.6%) |
| ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection | — | 0/50 (0%) | 40/50 (80%) |
| ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection | — | 0/54 (0%) | 40/54 (74.1%) |
| ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection | — | 2/49 (4.1%) | 35/49 (71.4%) |
| Placebo IVR + Leuprorelin Injection | — | 3/50 (6%) | 35/50 (70%) |
| Placebo IVR + Placebo Injection | — | 4/53 (7.5%) | 38/53 (71.7%) |
| Event | LNG 40 mcg IVR + Placebo Injection | ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection | Placebo IVR + Leuprorelin Injection | Placebo IVR + Placebo Injection |
|---|---|---|---|---|---|---|
| EndometriosisReproductive system and breast disorders | 1/49 | 0/50 | 0/54 | 0/49 | 1/50 | 1/53 |
| Ovarian cystReproductive system and breast disorders | 1/49 | 0/50 | 0/54 | 0/49 | 0/50 | 0/53 |
| Haemorrhagic ovarian cystReproductive system and breast disorders | 0/49 | 0/50 | 0/54 | 1/49 | 0/50 | 0/53 |
| Dyshidrotic eczemaSkin and subcutaneous tissue disorders | 0/49 | 0/50 | 0/54 | 1/49 | 0/50 | 0/53 |
| Pregnancy of unknown locationPregnancy, puerperium and perinatal conditions | 0/49 | 0/50 | 0/54 | 0/49 | 1/50 | 0/53 |
| HydronephrosisRenal and urinary disorders | 0/49 | 0/50 | 0/54 | 0/49 | 1/50 | 0/53 |
| Renal atrophyRenal and urinary disorders | 0/49 | 0/50 | 0/54 | 0/49 | 1/50 | 0/53 |
| PyelonephritisInfections and infestations | 0/49 | 0/50 | 0/54 | 0/49 | 0/50 | 1/53 |
| MenorrhagiaReproductive system and breast disorders | 0/49 | 0/50 | 0/54 | 0/49 | 0/50 | 1/53 |
| Pelvic painReproductive system and breast disorders | 0/49 | 0/50 | 0/54 | 0/49 | 0/50 | 1/53 |
| Event | LNG 40 mcg IVR + Placebo Injection | ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection | Placebo IVR + Leuprorelin Injection | Placebo IVR + Placebo Injection |
|---|---|---|---|---|---|---|
| Ovarian cystReproductive system and breast disorders | 20/49 | 20/50 | 24/54 | 16/49 | 5/50 | 7/53 |
| Hot flushVascular disorders | 1/49 | 0/50 | 3/54 | 3/49 | 17/50 | 2/53 |
| HeadacheNervous system disorders | 5/49 | 8/50 | 3/54 | 8/49 | 8/50 | 6/53 |
| NasopharyngitisInfections and infestations | 2/49 | 2/50 | 7/54 | 5/49 | 1/50 | 3/53 |
| AcneSkin and subcutaneous tissue disorders | 2/49 | 1/50 | 1/54 | 5/49 | 1/50 | 2/53 |
| EndometriosisReproductive system and breast disorders | 3/49 | 2/50 | 3/54 | 2/49 | 2/50 | 5/53 |
| Abdominal painGastrointestinal disorders | 0/49 | 1/50 | 1/54 | 4/49 | 0/50 | 0/53 |
| NauseaGastrointestinal disorders | 2/49 | 2/50 | 2/54 | 4/49 | 3/50 | 3/53 |
| Vaginal haemorrhageReproductive system and breast disorders | 1/49 | 3/50 | 2/54 | 4/49 | 0/50 | 0/53 |
| Libido decreasedPsychiatric disorders | 0/49 | 1/50 | 1/54 | 0/49 | 4/50 | 0/53 |
| Age, Continuous(years) | LNG 40 mcg IVR + Placebo Injection | ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection | Placebo IVR + Leuprorelin Injection | Placebo IVR + Placebo Injection | Total |
|---|---|---|---|---|---|---|---|
| Mean | 33.27 ± 7.4 | 32.96 ± 8.79 | 33.96 ± 5.73 | 33.72 ± 7.85 | 33.7 ± 6.29 | 34.89 ± 7.13 | 33.75 ± 7.23 |
| Sex: Female, Male(Participants) | LNG 40 mcg IVR + Placebo Injection | ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection | Placebo IVR + Leuprorelin Injection | Placebo IVR + Placebo Injection | Total |
|---|---|---|---|---|---|---|---|
| Female | 52 | 53 | 55 | 53 | 53 | 53 | 319 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | LNG 40 mcg IVR + Placebo Injection | ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection | Placebo IVR + Leuprorelin Injection | Placebo IVR + Placebo Injection | Total |
|---|---|---|---|---|---|---|---|
| Mean | 24.19 ± 4.52 | 26.07 ± 6.71 | 23.84 ± 6.15 | 25.47 ± 5.68 | 25.47 ± 5.51 | 24.43 ± 5.08 | 24.91 ± 5.67 |
| Mean Pain of the 7 Days With Worst Endometriosis Associated Pelvic Pain (EAPP)(units on a scale) | LNG 40 mcg IVR + Placebo Injection | ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection | Placebo IVR + Leuprorelin Injection | Placebo IVR + Placebo Injection | Total |
|---|---|---|---|---|---|---|---|
| Mean | 7.8205 ± 1.171 | 7.4664 ± 0.9893 | 8.1905 ± 1.068 | 7.5429 ± 1.2568 | 7.8964 ± 1.1952 | 7.6886 ± 1.2389 | 7.7842 ± 1.1702 |
| Percentage of Days With Pain Greater Than or Equal to (>=) 7(percentage of days) | LNG 40 mcg IVR + Placebo Injection | ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection | Placebo IVR + Leuprorelin Injection | Placebo IVR + Placebo Injection | Total |
|---|---|---|---|---|---|---|---|
| Mean | 50.094 ± 35.5201 | 40.1521 ± 29.8714 | 55.1155 ± 33.7625 | 37.3044 ± 30.2894 | 48.7001 ± 33.6685 | 41.1847 ± 33.0479 | 45.8234 ± 33.1247 |
| Percentage of Days With Pain >=4(percentage of days) | LNG 40 mcg IVR + Placebo Injection | ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection | ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection | Placebo IVR + Leuprorelin Injection | Placebo IVR + Placebo Injection | Total |
|---|---|---|---|---|---|---|---|
| Mean | 86.0058 ± 19.3136 | 84.7239 ± 18.1713 | 89.029 ± 16.3667 | 85.8451 ± 17.9466 | 92.9141 ± 11.6008 | 80.4397 ± 20.1004 | 86.6042 ± 17.6568 |
Showing the first 100 of 117 sites across 14 countries. Choose a country and city above to see the rest.
Ran from Oct 2014 to primary completion in Oct 2016, 24 months.
Results were first posted in Jan 2018, 1 year 2 months after primary completion. A results delay was requested in Jan 2017.
Of 44 phase 2 interventional studies under Endometriosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 37. This study's 24 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Levonorgestrel · Anastrozole